https://doi.org/10.4081/ejh.2020.3177
IncRNA MAPKAPK5-AS1 promotes proliferation and migration of thyroid cancer cell lines by targeting miR-519e-5p/YWHAH
Submitted: 9 September 2020
Accepted: 20 November 2020
Published: 3 December 2020
Accepted: 20 November 2020
Abstract Views: 929
PDF: 656
HTML: 5
HTML: 5
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Thyroid cancer is a common malignant tumour of the endocrine system and ranks ninth in cancer incidence worldwide. An extensive body of evidence has demonstrated that lncRNAs play a critical role in the progression of thyroid cancer. The lncRNA MAPKAPK5-AS1 has been reported to be abnormally expressed and to play a role in the development of various human cancers. However, MAPKAPK5-AS1’s potential role in thyroid cancer progression remains unknown. The objective of our study was to explore the role and mechanism of MAPKAPK5-AS1 in thyroid cancer cells and provide a potential target for its biological diagnosis and treatment. We transfected sh-MAPKAPK5-AS1 and sh-NC into BCPAP and TPC-1 cells for loss-of-function assays. Results of RT-qPCR analysis demonstrated that MAPKAPK5-AS1 was more highly expressed in thyroid cancer cells compared to normal cells. Functional assays demonstrated that interfering with the expression of MAPKAPK5-AS1 notably repressed proliferation and invasion and accelerated apoptosis of BCPAP and TPC-1 cells. Mechanistically, we found that miR-519e-5p was negatively regulated by MAPKAPK5-AS1 and that tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta (YWHAH) was a target of miR-519e-5p. Additionally, rescue assays demonstrated that downregulation of MAPKAPK5-AS1 expression inhibited cell proliferation, migration, and invasion and promoted apoptosis by sponging miR-519e-5p, thereby increasing YWHAH expression. Ultimately, our study revealed that MAPKAPK5-AS1 promotes proliferation and migration of thyroid cancer cells by targeting the miR-519e-5p/YWHAH axis, which provides novel insight into the development and progression of thyroid cancer.
Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017;235:R43-61.
Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results National Cancer Data Registry. Surgery 2010;148:1147-53.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
Zhang M, Wu WB, Wang ZW, Wang XH, Zhang M. lncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT. Eur Rev Med Pharmacol Sci 2017;21:1020-6.
Liu Q, Guo X, Que S, Yang X, Fan H, Liu M, et al. LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. Oncotarget 2017;8:43768-81.
Huang K, Geng J, Wang J. Long non-coding RNA RP11-552M11.4 promotes cells proliferation, migration and invasion by targeting BRCA2 in ovarian cancer. Cancer Sci 2018;109:1428-46.
Zhang J, Li XY, Hu P, Ding YS. lncRNA NORAD contributes to colorectal cancer progression by inhibition of miR-202-5p. Oncol Res 2018;26:1411-8.
Sun MY, Zhu JY, Zhang CY, Zhang M, Zhang H. Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells. Biotechnol Lett 2017;39:1477-84.
Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, et al. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol Cancer 2017;16:9.
Yuan Q, Liu Y, Fan Y, Liu Z, Wang X, Jia M, et al. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637. Int J Biochem Cell Biol 2018;98:1-9.
Zhanga HJ, Weia QF, Wanga SJ, Zhangb HJ, Zhanga XY. LncRNA HOTAIR alleviates rheumatoid arthritis by targeting miR-138 and inactivating NF-κB pathway. Int Immunopharmacol 2017;50:283-90.
Li X, Wang S, Li ZZ, Long XY, Wen LZ. The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer. Int J Biol Macromol 2017;105:346.
Jin Y, Feng SJ, Qiu S, Shao N, Zheng JH. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med Pharmacol 2017;21:3176-84.
Chen W, Zhu HY, Yin L, Wang TT, He X. lncRNA-PVT1 facilitates invasion through upregulation of MMP9 in nonsmall cell lung cancer cell. DNA Cell Biol 2017;36:787-93.
Zhang J, Li XY, Hu P, Ding YS. lncRNA NORAD contributes to colorectal cancer progression by inhibition of miR-202-5p. Oncol Res 2018;26:1411-8.
Gu ZH, Hou ZH, Zheng LB, Wang XQ, Wu LB, Zhang C. LncRNA DICER1-AS1 promotes the proliferation, invasion and autophagy of osteosarcoma cells via miR-30b/ATG5. Biomed Pharmacother 2018;104:110-8.
Guo H, Yang S, Li S, Yan MT, Li L, Zhang HX. LncRNA SNHG20 promotes cell proliferation and invasion via miR-140-5p-ADAM10 axis in cervical cancer. Biomed Pharmacother 2018;102:749-57.
Zhao X, Wang D, Ding Y, Zhou JM, Liu GH, Ji ZG. LncRNA ZEB1-AS1 promotes migration and metastasis of bladder cancer cells by post-transcriptional activation of ZEB1. Int J Mol Med 2019;44:196-206.
Ji H, Hui B, Wang J, Zhu Y, Tang L, Peng P, et al. Long noncoding RNA MAPKAPK5-AS1 promotes colorectal cancer proliferation by partly silencing p21 expression. Cancer Sci 2019;110:72-85.
Yang T, Chen WC, Shi PC, Liu MR, Jiang T, Song H, et al. Long noncoding RNA MAPKAPK5-AS1 promotes colorectal cancer progression by cis-regulating the nearby gene MK5 and acting as a let-7f-1-3p sponge. Clin Cancer Res 2020;39:139.
Aprelikova O, Yu X, Palla J, Wei BR, Niederhuber J. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle 2010;9:4387-98.
Deng X, Wu B, Xiao K, Kang J, Xie J, Zhang XP, et al. MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3. Cell Physiol Biochem 2015;35:71-82.
M. Carroll. Relationship of YWHAH single nucleotide polymorphisms to markers of rheumatoid arthritis disease severity. J Med Biol Stud 2018;1:101.
Lu YC, Cheng AJ, Lee LY, You GR, Li YL, Chen HY, et al. MiR-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44. Sci Rep 2017;7:2042.
Haonon O, Rucksaken R, Pinlaor P, et al. Upregulation of 14-3-3 eta in chronic liver fluke infection is a potential diagnostic marker of cholangiocarcinoma. Proteomics Clin Appl 2016; 10:248-56.
Ren L, Li Y, Zhao Q, Fan L, Tan B, Zang A, et al. miR-519 regulates the proliferation of breast cancer cells via targeting human antigen R. Oncol Lett 2020;19:1567-76.
Zhou JY, Zheng SR, Liu J, Shi R, Yu HL, Wei M, et al. MiR-519d facilitates the progression and metastasis of cervical cancer through direct targeting Smad7. Cancer Cell Int 2016;16:1-12.
Jiang H, Liang M, Jiang Y, Zhang T, Zhou RJ. The lncRNA TDRG1 promotes cell proliferation, migration and invasion by targeting miR-326 to regulate MAPK1 expression in cervical cancer. Cancer Cell Int 2019;19:152.
Wu TY, Qu LM, He GQ, Tian LL, Li L, Zhou H, et al. Regulation of laryngeal squamous cell cancer progression by the lncRNA H19/miR-148a-3p/DNMT1 axis. Oncotarget 2016;7:11553-66.
Liu D, Li Y, Luo G, Xiao XY, Tao D, Wu XC, et al. LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. Cancer Lett 2017;388:281-91.
Wang X, Lu X, Geng Z, Yang GY, Shi Y. LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration of papillary thyroid carcinoma via Wnt/β-catenin signaling. J Cell Biochem 2017;118:4745-52.
Dang S, Zhou J, Wang ZY, Dai SJ, He SX. MiR-299-3p functions as a tumor suppressor via targeting Sirtuin 5 in hepatocellular carcinoma. Biomed Pharmacother 2018;106:966-75.
Zhang ZJ, Li XY, Xiao Q, Wang ZM. MiR-574-5p mediates the cell cycle and apoptosis in thyroid cancer cells via Wnt/β-catenin signaling by repressing the expression of Quaking proteins. Oncology Lett 2018;15:5841-8.
Zhen Z, Dong F, Shen H, Wang QG, Hu J. MiR-524 inhibits Cell proliferation and induces cell apoptosis in thyroid cancer via targeting SPAG9. Eur Rev Med Pharmacol Sci 2018;22:3812-8.
Yu G, Zhang T, Jing Y, Bao QM, Tang Q, Zhang Y. miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP. Life Sci 2017;15:47-51.
Li YY, Shao JP, Zhang SP, Xing GQ, Liu HJ. miR-519d-3p inhibits cell proliferation and invasion of gastric cancer by downregulating B-cell lymphoma 6. Cytogenet Genome Res 2018;154:12-19.
How to Cite
Zhou, Y., Liu, S., Luo, Y., Zhang, M., Jiang, X., & Xiong, Y. (2020). IncRNA MAPKAPK5-AS1 promotes proliferation and migration of thyroid cancer cell lines by targeting miR-519e-5p/YWHAH. European Journal of Histochemistry, 64(4). https://doi.org/10.4081/ejh.2020.3177
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
